Advertisement
Canada markets close in 4 hours 49 minutes
  • S&P/TSX

    22,022.67
    +135.33 (+0.62%)
     
  • S&P 500

    5,437.78
    +62.46 (+1.16%)
     
  • DOW

    38,911.13
    +163.71 (+0.42%)
     
  • CAD/USD

    0.7303
    +0.0032 (+0.45%)
     
  • CRUDE OIL

    78.13
    +0.23 (+0.30%)
     
  • Bitcoin CAD

    95,554.85
    +4,339.30 (+4.76%)
     
  • CMC Crypto 200

    1,443.22
    +48.18 (+3.45%)
     
  • GOLD FUTURES

    2,343.00
    +16.40 (+0.70%)
     
  • RUSSELL 2000

    2,083.21
    +58.86 (+2.91%)
     
  • 10-Yr Bond

    4.2680
    -0.1360 (-3.09%)
     
  • NASDAQ

    17,661.65
    +318.10 (+1.83%)
     
  • VOLATILITY

    12.42
    -0.43 (-3.35%)
     
  • FTSE

    8,218.44
    +70.63 (+0.87%)
     
  • NIKKEI 225

    38,876.71
    -258.08 (-0.66%)
     
  • CAD/EUR

    0.6731
    -0.0033 (-0.49%)
     

Celldex to Participate in Upcoming November Investor Conferences

Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.

HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November:

  • Guggenheim 4th Annual Immunology and Neurology Conference on Monday, November 14, 2022 at 2:10 p.m. ET

  • Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 4:45 a.m. ET / 9:45 a.m. GMT

  • Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 4:45 p.m. ET

Webcasts of the presentations will be available on the "Events & Presentations" of the "Investors & Media" section of the Celldex website. Replays will be available for 30 days following the events.

ADVERTISEMENT

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com